

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0287 |
| Estimated average burden hours per response... | 0.5 |

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | | | | | |
|--|---------|----------|---|--|--|---|--|--|
| 1. Name and Address of Reporting Person * Gavin Robert M. | | | 2. Issuer Name and Ticker or Trading Symbol BIO-TECHNE Corp [TECH] | | | 5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director _____ 10% Owner _____ <input checked="" type="checkbox"/> Officer (give title below) _____ Other (specify below) _____ Senior V.P. Protein Platforms | | |
| (Last) | (First) | (Middle) | 3. Date of Earliest Transaction (Month/Day/Year) 08/18/2016 | | | | | |
| 614 MCKINLEY PLACE NE | | | 4. If Amendment, Date Original Filed(Month/Day/Year) | | | 6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person | | |
| (Street) | | | | | | | | |
| MINNEAPOLIS, MN 55413 | | | | | | | | |
| (City) | | | (State) | | | (Zip) | | |

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | | | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) |
|------------------------------------|---|---|-----------------------------------|---|--|------------|-------|--|---|--|
| | | | Code | V | Amount | (A) or (D) | Price | | | |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number. SEC 1474 (9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) |
|---|--|---|---|-----------------------------------|---|--|---|-----------------|--|---|---|---|---|
| | | | | Code | V | | Date Exercisable | Expiration Date | | | | | |
| Stock Option (Right to Buy) | \$ 93.32 | | | | | | (1) 07/31/2021 | Common Stock | 10,000 | | 10,000 | D | |
| Stock Option (Right to Buy) | \$ 93.32 | | | | | | (2) 07/31/2021 | Common Stock | 50,000 | | 50,000 | D | |
| Stock Option (Right to Buy) | \$ 90.25 | | | | | | (3) 11/30/2021 | Common Stock | 5,000 | | 5,000 | D | |
| Restricted Stock Units | (6) | | | | | | (4) (4) | Common Stock | 5,000 | | 5,000 | D | |
| Stock Option (Right to Buy) | \$ 108.49 | | | | | | (5) 08/07/2022 | Common Stock | 12,500 | | 12,500 | D | |
| Stock Option (Right to Buy) | \$ 108.49 | | | | | | (7) 08/07/2022 | Common Stock | 9,375 | | 9,375 | D | |
| Restricted Stock Units | (6) | | | | | | (7) (7) | Common Stock | 1,500 | | 1,500 | D | |
| Stock Option (Right to Buy) | \$ 106.59 | 08/18/2016 | | A | | 17,371 | (8) 08/18/2023 | Common Stock | 17,371 | \$ 0 | 17,371 | D | |
| Stock Option | \$ 106.59 | 08/18/2016 | | A | | 13,028 | (9) 08/18/2023 | Common | 13,028 | \$ 0 | 13,028 | D | |

| | | | | | | | | | | | | | |
|---------------------------------------|-----|------------|--|---|-------|-----|-----|--------------|-------|------|-------|---|--|
| (Right to Buy) Restricted Stock Units | (6) | 08/18/2016 | | A | 2,111 | (9) | (9) | Common Stock | 2,111 | \$ 0 | 2,111 | D | |
|---------------------------------------|-----|------------|--|---|-------|-----|-----|--------------|-------|------|-------|---|--|

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|-------------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Gavin Robert M. 614 MCKINLEY PLACE NE MINNEAPOLIS, MN 55413 | | | Senior V.P. Protein Platforms | |

Signatures

| | | |
|--|--|---------------------|
| /s/ Elizabeth M. Dunshee as Attorney-in-Fact for Robert M. Gavin pursuant to Power of Attorney previously filed. | | 08/22/2016 |
| <small>**Signature of Reporting Person</small> | | <small>Date</small> |

Explanation of Responses:

- * If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 2,500 shares vest on each of 7/31/15, 7/31/16, 7/31/17 and 7/31/18.
- (2) The options vest if certain performance goals are achieved for calendar 2016.
- (3) 1,500 shares vest on each of 12/1/15, 12/1/16, 12/1/17 and 12/1/18.
- (4) Vests in full or in part if certain performance goals are achieved for calendar 2016.
- (5) 3,125 shares vest on each of 8/7/16, 8/7/17, 8/7/18 and 8/7/19.
- (6) Each restricted stock unit represents a contingent right to receive one shares of Bio-Techne common stock.
- (7) Vests in full or in part on 8/7/18 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).
- (8) Vests 4,343 shares on each of 8/18/17, 8/18/18 and 8/18/19, and 4,342 shares on 8/18/20.
- (9) Vests in full or in part on 8/18/19 if certain performance goals are achieved (or such later date as performance is certified by the Administrator).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.